Department of Innovative Technologies in Medicine & Odontology, Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy.
Interventional Cardiology Department, Cath Lab, Ospedale SS. Annunziata, ASL 2 Abruzzo, Chieti, Italy.
Catheter Cardiovasc Interv. 2022 Mar;99(4):998-1005. doi: 10.1002/ccd.30137. Epub 2022 Feb 19.
We aim to define whether the timing of microaxial left ventricular assist device (IMLVAD) implantation might impact on mortality in acute myocardial infarction (AMI) cardiogenic shock (CS) patients who underwent primary percutaneous coronary intervention (PPCI).
Despite the widespread use of PPCI, mortality in patients with AMI and CS remains high. Mechanical circulatory support is a promising bridge to recovery strategy, but evidence on its benefit is still inconclusive and the optimal timing of its utilization remains poorly explored.
We compared clinical outcomes of upstream IMLVAD use before PPCI versus bailout use after PPCI in patients with AMI CS. A systematic review and meta-analysis of studies comparing the two strategies were performed. Effect size was reported as odds ratio (OR) using bailout as reference group and a random effect model was used. Study-level risk estimates were pooled through the generic inverse variance method (random effect model).
A total of 11 observational studies were identified, including a pooled population of 6759 AMI-CS patients. Compared with a bailout approach, upstream IMLVAD was associated with significant reduction of 30-day (OR = 0.65; 95% confidence interval [CI] = 0.51-0.82; I = 43%, adjusted OR = 0.54; 95% CI = 0.37-0.59; I = 3%, test for subgroup difference p = 0.30), 6-month (OR = 0.51; 95% CI = 0.27-0.96; I = 66%), and 1-year (OR = 0.56; 95% CI = 0.39-0.79; I = 0%) all-cause mortality. Incidence of access-related bleeding, acute limb ischemia and transfusion outcomes were similar between the two strategies.
In patients with AMI-CS undergoing PPCI, upstream IMLVAD was associated with reduced early and midterm all-cause mortality when compared with a bailout strategy.
我们旨在确定在接受直接经皮冠状动脉介入治疗(PPCI)的急性心肌梗死(AMI)合并心原性休克(CS)患者中,左心室辅助装置(LVAD)的微轴(IMLVAD)植入时机是否会影响死亡率。
尽管广泛应用了 PPCI,但 AMI 合并 CS 患者的死亡率仍然很高。机械循环支持是一种有前途的恢复策略,但关于其益处的证据仍不确定,其最佳应用时机仍未得到充分探索。
我们比较了在 AMI CS 患者中,在 PPCI 之前使用上游 IMLVAD 与在 PPCI 之后使用紧急(bailout)IMLVAD 的临床结局。对比较这两种策略的研究进行了系统评价和荟萃分析。使用 bailout 作为参考组,报告效应大小为比值比(OR),并使用随机效应模型。通过通用倒数方差法(random effect model)汇总研究水平的风险估计值。
共纳入 11 项观察性研究,包括 6759 例 AMI-CS 患者的汇总人群。与 bailout 方法相比,上游 IMLVAD 与 30 天(OR=0.65;95%置信区间 [CI] = 0.51-0.82;I²=43%,调整 OR=0.54;95%CI=0.37-0.59;I²=3%,组间差异检验 p=0.30)、6 个月(OR=0.51;95%CI=0.27-0.96;I²=66%)和 1 年(OR=0.56;95%CI=0.39-0.79;I²=0%)全因死亡率显著降低相关。两种策略的血管通路相关出血、急性肢体缺血和输血结局发生率相似。
在接受 PPCI 的 AMI-CS 患者中,与 bailout 策略相比,上游 IMLVAD 与降低早期和中期全因死亡率相关。